{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2F+Refractory+T-cell+Malignancies&page=22", "query": { "condition": "Relapsed/ Refractory T-cell Malignancies", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 845, "total_pages": 85, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2F+Refractory+T-cell+Malignancies&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapsed%2F+Refractory+T-cell+Malignancies&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T20:45:25.554Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04300998", "title": "Study of CAR-T Therapy in Older Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lymphoma", "Refractory B-Cell Lymphoma", "Lymphoma, B-Cell", "DLBCL NOS", "High-grade B-cell Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Activities of Daily Living/ADLs", "type": "BEHAVIORAL" }, { "name": "Instrumental Activity of Daily Living", "type": "BEHAVIORAL" }, { "name": "Timed Up and Go", "type": "BEHAVIORAL" }, { "name": "Cognition", "type": "BEHAVIORAL" }, { "name": "Geriatric Depression Scale", "type": "BEHAVIORAL" }, { "name": "Social Support", "type": "BEHAVIORAL" }, { "name": "Brief Test of Attention", "type": "BEHAVIORAL" }, { "name": "Trail Making Test", "type": "BEHAVIORAL" }, { "name": "Controlled Oral Word Association Test", "type": "BEHAVIORAL" }, { "name": "Hopkins Verbal Learning Test-Revised", "type": "BEHAVIORAL" }, { "name": "Blood draw", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 154, "start_date": "2020-03-04", "completion_date": "2027-03-04", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-10-15T20:45:25.554Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04300998" }, { "nct_id": "NCT00962507", "title": "Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "panobinostat", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2009-07", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2013-02-15", "last_synced_at": "2026-10-15T20:45:25.554Z", "location_count": 2, "location_summary": "Duarte, California • Pasadena, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00962507" }, { "nct_id": "NCT06191887", "title": "B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Transformed Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Mantle Cell Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma", "Refractory Transformed Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Autologous BAFFR-targeting CAR T Cells", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-03-18", "completion_date": "2040-12-31", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-15T20:45:25.554Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06191887" }, { "nct_id": "NCT04855136", "title": "Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "BB2121", "type": "BIOLOGICAL" }, { "name": "CC-220", "type": "DRUG" }, { "name": "BMS-986405", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2021-06-01", "completion_date": "2025-04-25", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-10-15T20:45:25.554Z", "location_count": 15, "location_summary": "Birmingham, Alabama • San Francisco, California • Jacksonville, Florida + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04855136" }, { "nct_id": "NCT04703192", "title": "Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Peripheral T-Cell Lymphoma", "Adult T Cell Leukemia/Lymphoma" ], "interventions": [ { "name": "Valemetostat Tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2021-06-03", "completion_date": "2027-08-31", "has_results": true, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-15T20:45:25.554Z", "location_count": 14, "location_summary": "Duarte, California • Palo Alto, California • San Francisco, California + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04703192" }, { "nct_id": "NCT00059995", "title": "MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "iratumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": "2003-01", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2013-05-30", "last_synced_at": "2026-10-15T20:45:25.554Z", "location_count": 3, "location_summary": "Rochester, Minnesota • New York, New York • Columbus, Ohio", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00059995" }, { "nct_id": "NCT04205409", "title": "Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Grade 3a Follicular Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Plasma Cell Myeloma", "Recurrent Mantle Cell Lymphoma", "Refractory Mantle Cell Lymphoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-06-05", "completion_date": "2026-01-05", "has_results": true, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-15T20:45:25.554Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04205409" }, { "nct_id": "NCT00005092", "title": "Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Psoralen", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "In vitro-treated peripheral blood stem cell transplantation (PBSCT)", "type": "PROCEDURE" }, { "name": "Radiation Therapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "49 Years", "sex": "ALL", "summary": "Up to 49 Years" }, "enrollment_count": 7, "start_date": "1999-05-28", "completion_date": "2002-08-28", "has_results": false, "last_update_posted_date": "2018-10-26", "last_synced_at": "2026-10-15T20:45:25.554Z", "location_count": 3, "location_summary": "Chicago, Illinois • St Louis, Missouri • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005092" }, { "nct_id": "NCT07488923", "title": "A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer (SCLC )", "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)", "Gastroenteropancreatic NEC (GEP NEC)", "Neuroendocrine Prostate Cancer (NEPC)" ], "interventions": [ { "name": "ML261", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Moonlight Bio, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2026-06-23", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-15T20:45:25.554Z", "location_count": 7, "location_summary": "St Louis, Missouri • Hackensack, New Jersey • New York, New York + 4 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07488923" }, { "nct_id": "NCT05400603", "title": "Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Refractory Neuroblastoma", "Relapsed Neuroblastoma", "Relapsed Osteosarcoma", "Refractory Osteosarcoma" ], "interventions": [ { "name": "Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": null, "sex": "ALL", "summary": "12 Months and older" }, "enrollment_count": 24, "start_date": "2023-11-06", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-12-26", "last_synced_at": "2026-10-15T20:45:25.554Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05400603" } ] }